Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
US Stock MarketDetailed Quotes
RGNX Regenxbio
- 8.810
- -0.060-0.68%
Trading Apr 24 12:12 ET
441.53MMarket Cap-1.92P/E (TTM)
8.944High8.520Low241.90KVolume8.830Open8.870Pre Close2.12MTurnover0.63%Turnover RatioLossP/E (Static)50.12MShares17.52052wk High1.70P/B338.71MFloat Cap5.03552wk Low--Dividend TTM38.45MShs Float85.100Historical High--Div YieldTTM4.78%Amplitude5.035Historical Low8.755Avg Price1Lot Size
About Regenxbio Company
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Company Profile
SymbolRGNX
Company NameRegenxbio
Listing DateSep 17, 2015
Issue Price22.00
Founded2008
CEOMr. Curran Simpson
MarketNASDAQ
Employees353
Fiscal Year Ends12-31
Address9804 Medical Center Drive
CityRockville
ProvinceMaryland
CountryUnited States of America
Zip Code20850
Phone1-240-552-8181
Websitehttp://www.regenxbio.com
Company Executives
- Name
- Position
- Salary
- Curran Simpson
- Director, President and Chief Executive Officer
- 4.78M
- Stephen Pakola, M.D.
- Executive Vice President and Chief Medical Officer
- 2.70M
- Patrick J. Christmas
- Executive Vice President, Chief Strategy Officer and Chief Legal Officer
- 2.74M
- Mitchell Chan
- Executive Vice President, Chief Financial Officer, Treasurer and Principal Accounting Officer
- 3.21M
- Dr. Olivier Danos, PhD
- Executive Vice President and Chief Scientific Officer
- 2.96M
- Kenneth T. Mills
- Chairman of the Board
- 5.51M
- Allan M. Fox
- Director
- 337.48K
- Jennifer Zachary
- Independent Director
- 329.98K
- George V. Migausky
- Independent Director
- 339.98K
- Daniel Tasse
- Lead Independent Director
- 347.48K
- Dr. Jean Bennett, M.D.,Pd.D
- Independent Director
- 324.98K
- Dr. David C. Stump,M.D.
- Independent Director
- 339.98K
- Dr. Argeris N. Karabelas, PhD
- Independent Director
- 339.98K
- Dr. Alexandra Glucksmann, PhD
- Independent Director
- 327.48K
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
